Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;107(9):1324-1330.
doi: 10.1136/bjophthalmol-2022-321225. Epub 2022 May 10.

Cardiovascular morbidity and all-cause mortality in patients with retinal vein occlusion: a Danish nationwide cohort study

Katrine Hartmund Frederiksen  1   2 , Lonny Stokholm  2   3 , Peter Hartmund Frederiksen  2   4 , Christina Mørup Jørgensen  5 , Sören Möller  3 , Ryo Kawasaki  2   6 , Tunde Peto  2   7 , Jakob Grauslund  5   2
Affiliations

Cardiovascular morbidity and all-cause mortality in patients with retinal vein occlusion: a Danish nationwide cohort study

Katrine Hartmund Frederiksen et al. Br J Ophthalmol. 2023 Sep.

Abstract

Background/aims: Associations between retinal vein occlusion (RVO) and subsequent cardiovascular disease (CVD) or mortality have not been evaluated in a recent cohort, after novel therapeutic options have increased referrals for treatment of the condition. We aimed to evaluate overall and subtype-stratified risk of CVD and all-cause mortality following RVO and assess any alterations after the introduction of angiostatic therapy in Denmark in 2011.

Methods: This nationwide, registry-based cohort study from 1998 to 2018 evaluated 4 194 781 individuals. Hazard ratios (HRs) were reported for RVO as an overall measure and subclassified as branch and central RVO.

Results: Patients with RVO (n=15 665) were median 71.8 years old at the time of exposure and 50.7% were women. RVO associated with incident CVD (adjusted HR 1.13, 95% CI 1.09 to 1.17) but not mortality (adjusted HR 1.00, 95% CI 0.97 to 1.03). Almost similar risks of CVD were found for patients with branch and central RVO (adjusted HRs 1.14, 95% CI 1.03 to 1.25, and 1.12, 95% CI 1.00 to 1.25, respectively), but only patients with central RVO exhibited increased mortality (adjusted HR 1.12, 95% CI 1.04 to 1.21). Risk of CVD, especially non-ischaemic, was higher for patients diagnosed after 2011 (adjusted HRs 1.24, 95% CI 1.15 to 1.33 vs 1.06, 95% CI 1.01 to 1.12).

Conclusion: In a cohort of the Danish population aged 40 years or more, patients with RVO had a 13% increased risk of incident CVD compared with unexposed individuals. Risk of CVD was increased after 2011, when intravitreal angiostatic treatment was introduced and referral practices altered.

Keywords: Epidemiology; Retina.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RK have received grants from Novartis Pharma and Senju Pharma, consulting fees from Nanolux and Office future and honoraria for lectures from Bayer within the previous 3 years, none of these directly related to the current work. KHF, LS, PHF, CMJ, SM, TP and JG declares no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1
Flowchart of cohort selection. CVD, cardiovascular diseases.
Figure 2
Figure 2
Hazard ratios and no. of events and person-years at risk of CVDs and all-cause mortality in patients with RVO, BRVO and CRVO compared to individuals without RVO. RVO, retinal vein occlusion, BRVO, branch retinal vein occlusion, CRVO, central retinal vein occlusion, CVD, cardiovascular diseases, PYR, person-years at risk.
Figure 3
Figure 3
Hazard ratios and no. of events and person-years at risk for CVDs and all-cause mortality in patients with RVO, BRVO and CRVO compared to individuals without RVO prior to and after March 17th 2011. RVO, retinal vein occlusion, BRVO, branch retinal vein occlusion, CRVO, central retinal vein occlusion, CVD, cardiovascular diseases, PYR, person-years at risk.
See this image and copyright information in PMC

References

    1. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol 2014;2014:1–5. 10.1155/2014/724780 - DOI - PMC - PubMed
    1. Campochiaro PA, Heier JS, Feiner L, et al. . Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102–12. 10.1016/j.ophtha.2010.02.021 - DOI - PubMed
    1. Brown DM, Campochiaro PA, Singh RP, et al. . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124–33. 10.1016/j.ophtha.2010.02.022 - DOI - PubMed
    1. Bertelsen M, Linneberg A, Rosenberg T, et al. . Comorbidity in patients with branch retinal vein occlusion: case-control study. BMJ 2012;345:e7885–9. 10.1136/bmj.e7885 - DOI - PMC - PubMed
    1. Bertelsen M, Linneberg A, Christoffersen N, et al. . Mortality in patients with central retinal vein occlusion. Ophthalmology 2014;121:637–42. 10.1016/j.ophtha.2013.07.025 - DOI - PubMed

Publication types